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ABSTRACT: Detoxifying enzymes such as ﬂavin-containing monoox-
ygenases deal with a huge array of highly diverse xenobiotics and toxic
compounds. In addition to being of high physiological relevance, these
drug-metabolizing enzymes are useful catalysts for synthetic chemistry.
Despite the wealth of studies, the molecular basis of their relaxed substrate
selectivity remains an open question. Here, we addressed this issue by
applying a cumulative alanine mutagenesis approach to cyclohexanone
monooxygenase from Thermocrispum municipale, a ﬂavin-dependent
Baeyer−Villiger monooxygenase which we chose as a model system
because of its pronounced thermostability and substrate promiscuity.
Simultaneous removal of up to eight noncatalytic active-site side chains
including four phenylalanines had no eﬀect on protein folding, thermo-
stability, and cofactor loading. We observed a linear decrease in activity, rather than a selectivity switch, and attributed this to a
less eﬃcient catalytic environment in the enlarged active-site space. Time-resolved kinetic studies conﬁrmed this interpretation.
We also determined the crystal structure of the enzyme in complex with a mimic of the reaction intermediate that shows an
unaltered overall protein conformation. These ﬁndings led us to propose that this cyclohexanone monooxygenase may lack a
distinct substrate selection mechanism altogether. We speculate that the main or exclusive function of the protein shell in
promiscuous enzymes might be the stabilization and accessibility of their very reactive catalytic intermediates.
KEYWORDS: enzyme promiscuity, substrate speciﬁcity, active site, tunnel mutagenesis, alanine scanning mutagenesis, Baeyer−Villiger
■ INTRODUCTION
Enzymes are traditionally thought of as being very speciﬁc for
the particular metabolic reaction they catalyze, and molecular
discrimination between closely related compounds indeed
often is an asset. However, it is also known that some degree of
substrate promiscuity is common for most if not all enzymes,
and this is assumed to be a prerequisite for their evolution.1
There are also enzymes equipped with an extremely broad
speciﬁcity, and some of them have become trailblazers in
modern biocatalysis.2 In many cases, the underlying physio-
logical role can explain the selective advantage that led to the
evolution of such indiscriminate catalysts. A classic example is
detoxiﬁcation, a process that involves diverse enzyme classes.3
In higher organisms, the metabolism of drugs proceeds via an
initial modiﬁcation phase involving cytochrome P450 (P450s)
and ﬂavin-containing monooxygenases (FMOs), while trans-
ferases and ligases ﬂag a compound for decomposition or
secretion in the subsequent conjugation phase.4 Performing
these steps on a range of xenobiotics allows these enzymes to
aﬀord a broad protection. P450s were originally investigated
because of their clinical relevance,5 but they also gained strong
interest in biocatalysis and protein engineering, due to their
unique catalytic competences.6 FMOs typically oxidize
heteroatoms,7 but a human isoenzyme (FMO5) recently was
shown to act as a Baeyer−Villiger monooxygenase (BVMO),8
adding to the repertoire of the reactions catalyzed by human
detoxifying and drug/xenobiotic-metabolizing enzymes.
BVMOs are enzymes present in all kingdoms9 and catalyze
the incorporation of oxygen adjacent to a carbonyl moiety via
their catalytic C4a-peroxyﬂavin intermediate, which results
from the reaction of dioxygen (O2) and reduced ﬂavin adenine
dinucleotide (FAD; Scheme 1).10
Interestingly, many characterized microbial BVMOs also
display relaxed substrate speciﬁcities, even though they are
typically thought to have a more specialized physiological role.
Cyclohexanone monooxygenase (CHMO) from Acinetobacter
sp. NCIMB 9871, for example, is part of a cyclohexanol
degradation pathway,11 yet this enzyme was found to convert
hundreds of diﬀerent compounds.12,13 With several crystal
structures14−18 and a wealth of mutagenesis data at hand,19−24
BVMOs present an excellent model for the study of substrate
acceptance and promiscuity. Engineering studies aiming at the
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implementation of a BVMO for cyclohexanone conversion are
particularly interesting; the resulting product, ε-caprolactone,
is a precursor for nylon-6, a polymer produced industrially on a
megaton scale.25
Several engineering attempts performed on a thermostable
BVMO which is inactive on cyclohexanone (phenylacetone
monooxygenase from Thermobif ida fusca26) failed to generate
a promiscuous mutant capable of acting on this substrate.21−23
The only mutant of phenylacetone monooxygenase known to
convert small amounts of cyclohexanone combined mutations
in the active site with mutations discovered through an unusual
approach of induced allostery.24,27 The allosteric residues are
approximately 18 Å from the substrate binding site and may
lead to a domain shift resulting in the alteration of the active-
site shape.24 Conformational ﬂexibility can indeed contribute
to enzyme promiscuity28 and could also play a role in the
kinetic mechanism of BVMOs18 as evidenced by crystal
structures of CHMO, which show a rotation of the NADP+
domain of around 3°.14 The related proteins lysine
monooxygenase and thioredoxin reductase show the same
domain architecture and were found to rotate by 30° and 67°,
respectively.29,30 Although there is no structural evidence for
similar movements in BVMOs, the ineﬃciency of rationally
engineering phenylacetone monooxygenase might result from
an incomplete picture of BVMO catalysis. Major shifts of the
cofactor,14 complex loop rearrangements,31 and the lack of an
explanation for the remote position of the conserved BVMO
ﬁngerprint motive18 leave room for speculations.
We therefore aimed to ﬁnd evidence for so far unknown
mechanisms involved in substrate preference and selectivity of
BVMOs and chose a recently described thermostable CHMO
as the target for this study.32 Because a lot of experimental data
on single mutants of various CHMOs as well as phenylacetone
monooxygenase can already be found in the literature (recently
reviewed in ref 33), we undertook the uncommon approach of
creating cumulative alanine mutants. Alanine lacks a distinct
side chain and does not allow the backbone geometries of
glycine. Thus, observed eﬀects can largely be attributed to the
loss of the wild-type side chain.34 In these minimalistic
mutants, we explored the eﬀects of incrementally removing
those groups that shape the binding site and presumably
establish favorable interactions with the substrates. While it
was previously observed that enzymes possess backups and can
compensate for the loss of some side chains through other
residues or conformations,28 accumulating mutations quickly
lead to inactivation.35 It was therefore against our expectations
to observe that our radical side-chain pruning only had a strong
eﬀect on enzyme activity when applied to a massive extent. In
combination with conclusions drawn from structural inves-
tigations, we show that in promiscuous enzymes such as
BVMOs, the accessibility to enzyme-stabilized, yet chemically
very reactive, ﬂavin intermediates appears the main factor that
governs substrate preference.
■ RESULTS
Structural Investigations Using a Substrate Mimic to
Reveal Substrate Binding Modes. In BVMOs, the catalytic
entity is the C4a-peroxyﬂavin, which reacts with the substrate
to form the so-called Criegee intermediate (Scheme 1).10
Although the chemistry behind this reaction is well under-
stood, crystal structures of monooxygenases with either ﬂavin
adduct are not available. It is possible that the unsuccessful
protein engineering is a direct result of the uncertainty about
the conformation of BVMOs in this critical catalytic step. Our
ﬁrst goal was, therefore, to rule out that BVMOs undergo a so
far overlooked conformational change. Because both the C4a-
peroxyﬂavin as well as the Criegee intermediates seem too
unstable to be crystallized and/or survive the X-ray exposure,
we aimed to create a mimic of the C4a-peroxyﬂavin−substrate
complex. In the course of our X-ray studies on a robust
CHMO from Thermocrispum municipale (TmCHMO; Figure
1a),32 we noticed that an acetate molecule present in the
crystallization medium binds in front of the C4a atom of the
ﬂavin ring. As the Criegee intermediate is negatively charged
and TmCHMO is active on linear aliphatic ketones, we
reasoned that the carboxylate could mimic the intermediate.
This idea prompted us to carry out cocrystallization trials with
various carboxylic acids. The trials were successful with
hexanoic acid, which bound to TmCHMO both in the tunnel
leading toward the active site as well as in the active site itself
Scheme 1. Baeyer-Villiger Reaction and Catalytic
Mechanism of BVMOs Showing the Various Oxidation
States of the Flavin (Fl)
Figure 1. Overall structure of TmCHMO crystallized in complex with
hexanoic acid (a, PDB code 6GQI) and superposition with a model of
the peroxyﬂavin (b) and the Criegee intermediate (c). (a)
Asymmetric unit of the TmCHMO crystal structure depicting the
secondary structure (left monomer) and as surface representation
(right monomer). The surface is cut open (gray planes) to emphasize
the position of the ligand molecules in the tunnel and active site. The
NADPH and FAD domains are colored red and pink, respectively.
NADP+, FAD, and hexanoic acids are shown as ball and sticks colored
green, yellow, and cyan, respectively. (b and c) The ﬂavin and NADP+
cofactors are shown as ball and sticks with yellow and green carbons,
respectively. In b, hexanoic acid as crystallized is shown as ball and
sticks (cyan carbons) superimposed on a model of the peroxyﬂavin. In
c, a model of the Criegee intermediate (Scheme 1) of hexanal is
shown together with the electron density of the bound hexanoic acid
(weighted 2Fo−Fc map, contoured at the σ = 1.2 level; Table S1).
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(Figure 1a; Table S1). The ligand close to the ﬂavin bound in
the same position as observed for previous BVMO crystal
structure ligands (Figure S1) and in an orientation we would
expect for the Criegee intermediate. For comparison, we
computationally modeled the peroxyﬂavin and the Criegee
intermediate (Figure 1b,c). We found that the anionic
peroxygroup stabilizes above the pyrimidine ring of the ﬂavin,
and this position coincides with one of the oxygen atoms of
hexanoic acid in our structure (Figure 1b). The other
carboxylate oxygen of hexanoic acid points away from the
ﬂavin to hydrogen bond with the hydrogens of the NE atom of
Arg329 and of the O1 atom of NADP+. This position was
previously predicted to be occupied by the negatively charged
oxygen of the Criegee intermediate by a theoretical study36
(Figure 1c). Importantly, we found no conformational changes
when comparing the overall protein arrangement of the
TmCHMO−hexanoic acid complex with that of previously
obtained structures. The Cα-atom root-mean-square deviation
from the previously obtained structure of TmCHMO in
complex with FAD and NADP+ in the oxidized (ligand-bound,
PDB code 5M0Z) and reduced (diﬀerent space group; 5M10)
complexes was only 0.3 Å. We thus concluded that in the
reaction outcome-determining catalytic step of the Criegee
intermediate, the enzyme is unlikely to be in a diﬀerent
conformation than previously observed.
Pruning the Side Chains from the Substrate-Binding
Site. Having ruled out large enzyme conformational changes
during the Criegee intermediate step, we next turned our
attention to the active-site pocket using the crystal structure as
a reference. In TmCHMO, 10 residues form the catalytic site:
Leu145, Leu146, Phe248, Phe279, Arg329, Phe434, Thr435,
Leu437, Trp492, and Phe507 (Figure 2). Notably, these
residues are strictly conserved in all bona f ide CHMOs, i.e.,
closely related enzymes that were demonstrated to be active on
cyclohexanone (Figure S2). Since it was shown that the strictly
conserved aromatic residue at positions 49220 and Arg32937
are essential for catalysis, these two positions were excluded for
mutagenesis. The remaining eight residues were successively
and cumulatively mutated to alanine. The order was chosen
arbitrarily with the exception of the last added Leu146 and
Leu437, which are within interacting distance from the two
cofactors, and Thr435, whose side chain points away from the
active site (Figure 2). Notably, four of the targeted residues are
phenylalanines, resulting in a substantial increase in the volume
of the active site upon mutation to alanine (Figure 2).
Although the replacement of single active-site residues can lead
to a more stable enzyme,38 previous studies showed that
mutating the binding site residues in BVMOs usually slightly
decreases enzyme stability.39 Moreover, accumulating muta-
tions are frequently found to be deleterious in general.35
Therefore, we were expecting to encounter abolished activity
at some point, but were hoping for retained protein folding
ability.
We applied successive rounds of site-directed mutagenesis to
a plasmid harboring the TmCHMO gene fused to a (His6)-
SUMO expression tag. This resulted in eight variants ranging
from the single (1×) mutant L145A up to the 8-fold (8×)
mutant L145A/L146A/F248A/F279A/F434A/T435A/
L437A/F507A (Table S2). As they emerged in the course of
mutagenesis, we also tested three more variants corresponding
to alternative 2×, 5×, and 7× mutants (Table 1). Upon
transformation in Escherichia coli, we found that all variants
expressed equally well as wild-type TmCHMO and could be
puriﬁed loaded with FAD. We determined the melting
temperature (Tm) of the mutant proteins with a thermal shift
assay that exploits ﬂavin ﬂuorescence (ThermoFAD).40
Figure 2. Active-site pocket and tunnel of TmCHMO wild type (crystal structure, top panel) and the 8× alanine mutant (model, bottom panel).
The left and right panels are the same scene rotated by 180°. FAD and NADP+ are depicted in yellow and green, respectively. All active-site
residues are displayed as sticks in various colors. The surface they create and which forms the pocket is in the same color. In the mutant, residues
that contribute to the newly shaped pocket are also shown with gray carbons. The hexanoic acid ligand bound in the tunnel is depicted as ball and
sticks. The rest of the protein is shown as a gray surface representation, cut open at various planes (black). The active-site pocket is not cut, to
emphasize the volume diﬀerences between wild type and mutant. As a result, the inner hexanoic acid ligand, bound close to the ﬂavin (Figure 1b,c),
cannot be seen.
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Despite the accumulating loss of active-site side chains, we
found that the Tm gradually increased with each introduced
alanine mutation until the 5× mutant, which had a 4 °C higher
Tm than wild-type TmCHMO (Figure 3a). Then, the stability
slightly declined again until the 8× mutant, which still had a
3 °C higher Tm than the wild-type enzyme. From these data,
we concluded that protein folding and stability were apparently
not aﬀected by the mutations.
We then wanted to determine the point of abolition of
catalytic activity. To that end, we determined enzyme activity
using a spectrophotometric NADPH consumption assay, but
also performed bioconversions and product analysis via gas
chromatography−mass spectrometry. Besides cyclohexanone,
we also used rac-bicyclo-[3.2.0]hept-2-en-6-one, a model
substrate for the analysis of stereo- and regioselectivity and
readily converted by most BVMOs. Surprisingly, we found that
none of the mutations caused a complete loss of activity. First,
the kinetic analysis showed that the uncoupling rate, i.e., the
unproductive NADPH oxidation, was barely aﬀected by most
mutations (Figure 3b, Table S2). Measurements in the
presence of rac-bicyclo-[3.2.0]hept-2-en-6-one or cyclohex-
anone, on the other hand, showed an impaired catalytic
performance: while the 1× mutant displayed a somewhat
higher activity than the wild-type enzyme, the rates quickly
declined upon accumulative loss of active-site side chains, until
it became undistinguishable from the uncoupling rate from the
4× mutant on (Figure 3b and Table S2). Likewise, the
bioconversions showed the complete turnover of 1 mM
cyclohexanone in 24 h at 30 °C by all mutants up to and
including the 4× mutant, yet also approximately 10%
conversion by the 5× mutant, and trace conversions detectable
up to the 8× mutant (Figure 3c). Reactions with rac-bicyclo-
[3.2.0]hept-2-en-6-one were performed with 10 mM substrate,
and while the 4× mutant converted only traces, the two 5×
(85% and 29%) and the 6× mutant (97%) still showed high
turnovers (Figure 3c). In the highest mutants, no product was
detectable at ﬁrst, but when we extended the reaction time to
72 h and supplemented the conversion mix with FAD and
catalase, we could also detect traces of conversions of rac-
bicyclo-[3.2.0]hept-2-en-6-one. These results led us to reject
the hypothesis that a combination of side chains in the active
site is required for catalysis in general, or for activity on
Table 1. Active-Site Residues Targeted in This Study (Grey
Field Indicates a Mutation to Alanine in the Corresponding
Variant)
Figure 3. A summary of the thermostability, kinetic, and bioconversion properties of the TmCHMO active-site mutants (see Table 1). The
thermostability and kinetic properties of the mutants are shown in a and b. BCH is rac-bicyclo-[3.2.0]hept-2-en-6-one. (c) Conversions of
individual substrates are quantitative and plotted on a logarithmic scale. The enzyme concentration was 2 μM. 2-Butanone conversions were
performed using whole cells. More information can be found in the Supporting Information. (d) Conversions of substrate mixes are
semiquantitative and approximated based on GC peaks as full (>99%), moderate (50−99%), low (5−50%), or trace (<5%). The enzyme
concentration was 10 μM. Panel e illustrates product regioselectivity (abnormal vs normal lactone). (f) Legend for c−e. All data sets with an error
bar (corresponding to ± sd) are from two, the remaining data from one independent experiment.
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cyclohexanone in particular. In fact, these results indicate that
none of the targeted residues is strictly essential for either task.
We also analyzed the eﬀect on CHMO’s substrate
promiscuity and performed conversions with two substrate
mixes. These contained common BVMO substrates [4-
octanone, phenylacetone, (+)-dihydrocarvone], as well as
substrates for noncanonical oxidations (thioanisole, benzalde-
hyde, isophorone) together with compounds typically not
accepted by CHMOs [(−)-menthone, (−)-isomenthone,
acetophenone, 1-indanone, cyclopentadecanone, camphor,
stanolone]. The results are summarized in Figure 3d. The
substrate scope of wild-type TmCHMO was found to be even
broader than assumed. Besides converting cyclic substituted
and linear ketones and performing sulfoxidations, TmCHMO
also oxidizes benzaldehyde andin contrast to CHMO from
Acinetobacter sp. NCIMB 987141converts aromatic ketones
such as 1-indanone and acetophenone. The only tested
substrates that were not converted were very bulky or α,β-
unsaturated ketones. While previous work already showed a
high aﬃnity of wild-type TmCHMO for some of the assayed
compounds,32 the detection of a comparable amount of
product resulting from the conversion of the newly identiﬁed
substrates suggest that their binding constants are on the same
order of magnitude. The alternative scenario, i.e., very high kcat
and KM values, is improbable taking into account that wild-type
TmCHMO shows similar kcat values (and thus the same rate-
limiting step) with most of the assayed substrates. In the
mutants, on the other hand, the promiscuous activity gradually
vanishes. Although sulfoxidation capability and activity on
cyclic ketones is mostly retained in the highest mutants,
activity on nearly all other substrates is practically lost. The 4×
mutant showed no activity in these conversions; apparently
this particular combination of mutations is unfavorable in some
conditions (presumably in the presence of the more elevated
concentration of acetonitrile used in these reactions). Notably,
for some mutants we observed an activity on cyclo-
pentadecanone, a transformation that was never previously
reported for a CHMO. When testing these mutants in
individual conversions with 1 mM of this bulky substrate,
the 3× mutant converted approximately 60% to the
corresponding lactone (Figures 3c, S3).
Because some of the substrates we used can yield two
diﬀerent products depending on the side of oxygen
incorporation, we could also study the eﬀect of the mutations
on regioselectivity. We found that if the wild-type enzyme
produced exclusively the normal product (where the oxygen is
incorporated next to the more substituted carbon), the
regioselectivity remained unaﬀected in the mutants. When
the enzyme produced fully or partially the abnormal product,
however, the selectivity turned in favor of the normal product
as more side chains were removed. As is the case for other
CHMOs,42 wild-type TmCHMO produces exclusively the
abnormal lactone from trans-(+)-dihydrocarvone. In the 1×
and one of the 2× mutants, this selectivity is retained, while all
the other mutants produce between 31 and 43% abnormal
lactone. This apparent on/oﬀ mechanism seems to depend on
Phe279: if it is present, regioselective production of the
abnormal lactone occurs, while in its absence the residual
production is unselective and approximates the value found for
Baeyer−Villiger reactions via chemical oxidation.43 For 4-
octanone, the abnormal production slightly increases upon the
ﬁrst mutation approximating full regioselectivity but then drops
to 32 and 15% in the 2× and 3× mutants. Using a whole cell
assay, we also performed conversions with 11 mM 2-butanone
(Figure 3c), which yields the industrially relevant methyl
propanoate when the abnormal product is formed. We found
exclusively the normal product from the 5× mutant on (Figure
3e). Wild-type TmCHMO converts rac-bicyclo-[3.2.0]hept-2-
Figure 4. Tunnel mutagenesis strategy and activity results. (a) Surface representation of the substrate tunnel of TmCHMO occurring in the crystal
structure. (b) Schematic cross-section through TmCHMO’s active site and substrate tunnel and contributing residues. All residues depicted in the
same color and corresponding to ring-like dissections of the tunnel were simultaneously mutated to alanine. (c and d) Conversion results for
substrate mixes (c, semiquantitative, see Figure 3) and of cyclohexanone and rac-bicyclo-[3.2.0]hept-2-en-6-one (rac-BCH) in individual
conversions (d, quantitative). Enzyme concentrations were 2 μM and 10 μM for mixed and individual substrates, respectively. (e) Stability of the
ring-wise tunnel multialanine mutants; the dashed line indicates the melting temperature of the wild-type enzyme.
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en-6-one regiodivergently, leading to the abnormal lactone
from one substrate enantiomer, and the normal lactone from
the other. We found that the enzyme was able to retain this
behavior until the 6× mutant. Previous protein engineering
studies aiming to change the regioselectivity in BVMOs often
sought to rationalize the switch toward normal lactone
production by computational models.44−46 Our ﬁndings
support the simple conclusions that, in a spacious and
nonspeciﬁc binding site, the normal product is preferentially
formed, leading to the same regioselectivity as the non-
enzymatic Bayer-Villiger reaction. The shift toward the
abnormal product can thereby take place only in the context
of a sterically restrained environment. A recent study used
extensive computational analysis to investigate the origin of
abnormal product formation in TmCHMO mutants and
corroborates this conclusion.47
Expanding to the Active-Site Tunnel. Our results
indicate that the active-site residues are not strictly essential
for catalysis and contribute to CHMO’s substrate preference
only to a limited extent since most mutants retained a broad
substrate scope with highest activities toward cyclohexanone
and thioanisole. If this selectivity was not determined in the
active site, however, it consequently would have to be
established elsewhere. A hint about this hypothesis was given
by our crystal structure of TmCHMO in complex with
hexanoic acid. The asymmetric unit of the crystals contains two
enzyme monomers. Both monomers contain the hexanoic
ligand in the active site, but one of them also features a deﬁned
density for the same ligand in the tunnel that connects the
active site to the solvent (Figures 2, 4a). This tunnel has
previously been observed in BVMOs,17,48 but our structure is a
unique capture of a molecule along this diﬀusion pathway.
This newly emerged evidence for the importance of the
tunnel prompted us to investigate its role in substrate
acceptance. After a careful visual inspection, we deﬁned as
tunnel residues only those amino acids that protrude with their
side chain into the path of the tunnel. Residues contributing
with their backbone only were excluded, because mutagenesis
would not aﬀect the tunnel shape and easily disturb the
hydrophobic packing. The beginning of the tunnel was deﬁned
as the rim at the solvent exposed outside and the end as the
catalytic site (Figures 2 and 4).
If the tunnel indeed was partially or fully responsible for
CHMO’s activity on cyclohexanone, we hypothesized that we
could also transfer this activity by transplanting the tunnel. As
an engineering target, we chose phenylacetone monooxyge-
nase, which is inactive on cyclohexanone and shares 44%
sequence identity with TmCHMO. Because some active-site
residues also partially contribute to the shape of the tunnel
further up, we created two variants for the transplantation
approach: one with those residues exchanged that only form
the tunnel, and one in which also the entire catalytic site was
exchanged (Tables S3−S5). The latter mutant included the
double deletion of Ser441 and Ala442, the so-called active-site
“bulge” present in phenylacetone monooxygenase,21 and two
mutations corresponding to amino acids that only contribute
to the active site found in phenylacetone monooxygenase
(Ile339 and Leu340). Similarly, Phe250 does not contribute to
the tunnel in TmCHMO, but because the corresponding
Arg258 in phenylacetone monooxygenase does, it was also
exchanged in both variants. The two enzymes furthermore
display several glycine insertions and deletions in the tunnel
and/or the active site, and those were also exchanged (details
can be found in the Supporting Information). The resulting
25× and 38× mutant genes of phenylacetone monooxygenase
were ordered as synthetic genes, cloned and transformed, and
expressed in E. coli. We found expression and ﬂavin
incorporation unaﬀected, but when we tried the proteins in
bioconversions, only the 25× mutant showed minor activity
with rac-bicyclo-[3.2.0]hept-2-en-6-one, which was converted
to the two normal lactones (Table S6). No activity was found
with any of the other substrates. Clearly, simply transplanting
the tunnel-surface residues from one enzyme to the other was
not causing a transfer of substrate selectivity. On the other
hand, it is remarkable that such an overwhelming set of
mutations did not abolish FAD binding and protein stability
(Table S6), highlighting a remarkable degree of structural
tolerance featured by the BVMO protein scaﬀold.
As a second strategy, we followed our previous approach of
cumulative alanine substitutions. We dissected the tunnel in
ﬁve ring-like sections, because a mutation of all residues to
alanine at once was likely to lead to insoluble protein. Each
section contained 5−10 residues, and those were simulta-
neously mutated to alanine (Figure 4a). We created the
plasmids using a PCR based method using mutated primers
and subsequent Gibson assembly.49 The proteins expressed
well with incorporated ﬂavin. The more external ring-1
residues turned out to have little inﬂuence on the enzyme
properties (Figure 4b,c). Conversely, the other mutants were
mostly inactive on substituted cyclic, aromatic, and linear
ketones. However, they retained a high activity on cyclo-
hexanone and moderate activities on thioanisole, rac-bicyclo-
[3.2.0]hept-2-en-6-one, 4-octanone, and acetophenone (Figure
4c). In the case of ring 3, the mutant was unable to convert
more than small amounts of rac-bicyclo-[3.2.0]hept-2-en-6-one
(Figure 4c), but it gained weak activity on cyclopentadecanone
(Figure 4b), possibly indicating that this particular part of the
tunnel presents a bottleneck for the entry of bulky substrates.
Low activity on rac-bicyclo-[3.2.0]hept-2-en-6-one was also
found for the ring 2 multiple-Ala mutant, but this could result
from its decreased stability (Figure 4d). The regioselectivity
remained relatively unaﬀected in these mutants (Figure 4c). In
general, these experiments followed the same trend observed
for the active-site poly-Ala mutants. Introducing multiple
alanine residues on the tunnel wall does not aﬀect the
preference for cyclohexanone, thioanisole, and rac-bicyclo-
[3.2.0]hept-2-en-6-one, which remain the best substrates for all
mutants despite their small bulkiness.
Inﬂuence on the Flavin-Peroxide Stabilization. For a
more in-depth understanding of the eﬀect of side-chain
pruning on the catalytic cycle, we used a stopped-ﬂow
spectrophotometer to study both the reductive and oxidative
half-reactions of the 6× variant, which is the highest
mutagenized enzyme variant with well detectable activity
(Figure 3). The mutant became fully reduced in the presence
of NADPH under anaerobic conditions, as evidenced by the
loss of the absorbance peak at 440 nm (Figure S4). The
stopped-ﬂow traces at 440 nm were best ﬁt to a double
exponential function with an initial faster phase accounting for
71% of the total absorbance change. The corresponding kred1
and kred2 values were 0.2 and 0.02 s
−1, respectively. These data
can be compared with the stopped-ﬂow traces at 440 nm for
wild-type TmCHMO, which were best ﬁt to a triple
exponential function with kred values of 30, 2, and 0.1 s
−1.
The Kd value for NADPH was too small to be determined
under pseudo-ﬁrst-order conditions (≥5-fold excess of
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NADPH over enzyme) for both the 6× and wild-type enzymes.
To study the oxidative half-reaction, the 6× variant was
anaerobically mixed with a stoichiometric amount of NADPH.
Next, the resulting two-electron reduced enzyme was reacted
with an air-saturated buﬀer resulting in an immediate increase
in absorbance at 440 nm (Figure S4). The trace was best ﬁt to
a double exponential function corresponding to rates of 0.4
and 0.1 s−1. Diﬀerently from wild-type TmCHMO,32 a stable
C4a-peroxyﬂavin with an absorption maximum at around 355
nm was not observed in the 6× variant at either 25 or 4 °C,
most likely because its decay is faster than its formation.
Collectively, these experiments showed that both the reductive
and the oxidative half-reactions are impaired in the 6× variant.
This may be due to a nonoptimal position of the NADPH in
the enzyme, which hampers both hydride transfer and
stabilization of the C4a-peroxyﬂavin. Nevertheless, the mutants
must retain some stabilization of the C4a-peroxyﬂavin
(documented by the detection of Baeyer−Villiger reaction
products in the above bioconversions; Figures 3 and 4), giving
further evidence that the intermediate is above all stabilized by
the bound NADP+, potentially supported by residues at the
ﬂavin’s si side.
■ DISCUSSION
Our results from the mutagenesis of the active site and the
tunnel collectively suggest that we were not targeting a
structural entity that is fully responsible for the selectivity
diﬀerences in BVMOs. Although similar approaches to our
tunnel transplantation attempt have failed also in other cases,50
our section-wise “alanization” clearly shows the retention of
activity with cyclohexanone and other good substrates.
Although we observe decreased substrate promiscuity, these
eﬀects are likely to stem from an overall reduced catalytic
eﬃciency, as evidenced by the reduced observed rates. Since
the activity on cyclohexanone is not overwhelmingly
determined by CHMO’s active site or tunnel, it is possible
that there is another, more remote substrate recognition and
ﬁlter site. This could potentially also involve protein dynamics
that previous BVMO structures were simply unable to capture.
The second andaccording to Occam’s razormore likely
possibility is that CHMOs simply lack a selection mechanism
entirely. Both BVMOs and ﬂavin-containing monooxygenases
were previously described as “cocked guns,”51 giving credit to
their continuous stabilization of the C4a-peroxyﬂavin, which
readily reacts with any substrate reaching the active site. Our
experiments expand the idea to a “cocked shotgun” and suggest
that enzymes like CHMO simply provide a scaﬀold to stabilize
the reactive cofactor, and potentially lack a speciﬁc mechanism
for substrate uptake and acceptance entirely. The only ﬁlter
would then be the size of the active site and the increasing
hydrophobicity toward the inside. Because most biological
metabolites are polar, this rather crude selection of favoring
partition from the solvent might be suﬃcient to prevent these
enzymes from unwanted cellular reactions.
Promiscuous activity on polar compounds can easily
interfere with primary metabolism; thus, enzymatic activity
on such molecules needs to be more tightly regulated. On the
one hand, enzymes can evolve speciﬁc mechanisms that limit
broad speciﬁcity, as is the case for BVMO-related hydrox-
ylases/monooxygenases.52 Accumulation of paralogs with a
more restricted substrate scope can achieve diversity without
complete unspeciﬁcity, as could for example be the case for a
set of BVMOs found in a single plant biomass-degrading
bacterial species.41,53 On the other hand, expression of
promiscuous isoforms can be restricted to certain tissues,54
or regulation can occur through wide substrate-dependent
variations in the catalytic rate, as has been observed for
detoxifying paraoxonases.55 An “excluding rather than binding”
mechanism as we show is the case for some BVMOs, however,
could well be the case for many catabolic or detoxifying
enzymes which show high promiscuity toward hydrophobic
substrates, such as ﬂavin-containing monooxygenases56 or
cytochrome P450s.57 Our completely “alanized” active-site
mutant of TmCHMO can also be a useful starting point for
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